CLN-418 Study on Subjects With Advanced Solid Tumors

Inclusion Criteria:

1. Willingness to sign a written informed consent document.

2. Male or female subject aged ≥18 years old at the time of screening.

3. Histologically or cytologically confirmed advanced solid tumors (e.g., breastcancer, ovarian cancer, endometrial cancer, cervical cancer, squamous cell non-smallcell lung cancer (sNSCLC), cholangiocarcinoma, esophagus cancer, urothelialcarcinoma, head and neck squamous cell carcinoma (HNSCC)), followed bydose-expansion cohorts (Part 2) of subjects with advanced and/or metastaticnon-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC).orrecurrent and progressed since last antitumor therapy for which no alternative,curative standard therapy exists.

4. Adequate organ and bone marrow function.

Exclusion Criteria:

1. Prior used anti-B7H4 and/or anti-4-1BB antibody treatment.

2. Immuno-oncology therapy or targeted anti-cancer therapy within 4 weeks prior tofirst dose of investigational product, any other anti-cancer therapy within 2 weeksprior to first dose of investigational product.

3. Not yet recovered from surgery or (immune-related) toxicity related with previoustreatment.

4. Known history or active infection of hepatitis B or C.

5. History of cirrhosis or non-alcohol steatohepatitis, alcohol or drug-related,autoimmune hepatitis.

6. Known brain metastases or other central nervous system metastases that are eithersymptomatic or untreated that require concurrent treatment.

7. Active infection that requires treatment with antibiotics or antiviral treatmentwithin 3 weeks prior to first dose of investigational product.

8. Known history of infection with human immunodeficiency virus or known acquiredimmunodeficiency syndrome (AIDS).

9. Known autoimmune disease.

10. Clinically significant cardiac condition.

11. Pregnant or breastfeeding women.